ArticleJournal for immunotherapy of cancer2025

MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence.

Margaux Tual et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.